Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Locally Advanced or Metastatic Breast Cancer
Interventions: DRUG: Lasofoxifene|DRUG: Fulvestrant
Sponsor: Sermonix Pharmaceuticals Inc.
Collaborators: Linical Accelovance Group